Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Notes Payables (2021 - 2023)

Avalo Therapeutics filings provide 3 years of Notes Payables readings, the most recent being $14.1 million for Q2 2023.

  • On a quarterly basis, Notes Payables changed N/A to $14.1 million in Q2 2023 year-over-year; TTM through Jun 2023 was $14.1 million, a N/A change, with the full-year FY2022 number at $5.9 million, changed N/A from a year prior.
  • Notes Payables hit $14.1 million in Q2 2023 for Avalo Therapeutics, up from $9.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $33.2 million in Q1 2022 to a low of $2.6 million in Q3 2022.
  • Median Notes Payables over the past 3 years was $14.1 million (2023), compared with a mean of $16.4 million.
  • Biggest five-year swings in Notes Payables: tumbled 92.11% in 2022 and later crashed 71.99% in 2023.
  • Avalo Therapeutics' Notes Payables stood at $32.5 million in 2021, then crashed by 81.74% to $5.9 million in 2022, then soared by 138.03% to $14.1 million in 2023.
  • The last three reported values for Notes Payables were $14.1 million (Q2 2023), $9.3 million (Q1 2023), and $5.9 million (Q4 2022) per Business Quant data.